Sanegene Bio

SanegeneBio is a biotechnology company emerging from the field of RNA interference (RNAi) therapeutics. Founded in 2021 and headquartered in Woburn, Massachusetts, the company employs a team of five dedicated professionals. SanegeneBio focuses on developing innovative RNAi therapies leveraging cutting-edge delivery technology. Their proprietary chemical modification platform and hepatic and extrahepatic delivery platforms enable targeted delivery of RNA therapeutics to specific tissues. This technology allows for the efficient silencing of disease-causing genes, offering potential treatments for a variety of conditions. The company's rapidly expanding RNAi portfolio encompasses a broad spectrum of therapeutic areas, including cardiovascular and metabolic diseases, immunology-related diseases, and nervous system diseases. Notably, SanegeneBio's first RNAi drug has progressed to the clinical trial stage, while several other promising pipelines are actively being developed. To learn more about SanegeneBio's groundbreaking RNAi therapeutics, visit their website at sanegenebio.com.